Objective:

To explore current trends shaping the development, manufacturing, and commercialization in biotech and biopharma.

Approach:

• Industry Insights: Industry leaders share perspectives on the evolving landscape of biotech and biopharma, focusing on complexities in development and commercialization.

Key Findings:

• Molecules are becoming more complex, particularly with formats such as bispecifics and fragments, increasing demands on development and manufacturing.
• Companies are prioritizing partners with deep technical knowledge and proven experience within specific modalities.
• There is a shift towards asset-specific development strategies to generate early clinical data that informs next steps.
• The funding environment is challenging, emphasizing capital efficiency and the ability to demonstrate a credible path to commercialization.
• Geopolitical uncertainties and supply chain disruptions pose ongoing risks, reinforcing the importance of building flexibility and risk mitigation into strategies.

Interpretation:

Limitations:

• The funding environment remains constrained, particularly for emerging biotechs, and there is a need for flexibility and risk mitigation in development and manufacturing strategies.

Conclusion: